From Freefall to Focused Recovery
Parke-Davis: How CVA Helped Lopid Fight Back Against Statins
The Challenge:
Lopid had once ruled the cholesterol-regulating market, owning over 70% of prescriptions. But when Merck launched Mevacor, the first in a powerful new class of statins, Lopid’s share collapsed — from the 70s to the mid-20s in less than two years.
Internally, panic set in. The team believed they were outgunned — Mevacor was new, innovative, and getting all the attention. Joe Smith, the newly appointed president, had worked with CVA before. He knew the brand needed more than a rebrand — it needed a fact-based understanding of its true value position.
The CVA Breakthrough:
The CVA team started with a straightforward question: Is Lopid really obsolete, or just misunderstood?
They built a Value Scorecard for cholesterol treatments, identifying key benefit attributes:
- LDL (bad cholesterol) reduction
- HDL (good cholesterol) improvement
- Side effects
- Drug interactions
- Dosing convenience
- Long-term risk reduction
- Price
Using medical literature and peer-reviewed clinical trials, the team confirmed:
- Mevacor was stronger at reducing LDL
- Lopid was better at raising HDL — which is equally important for high-risk patients
So far, it looked like a fair fight — each drug had different strengths. But when CVA collected prescribing physician surveys, a critical gap emerged:
Doctors correctly believed Mevacor was better for LDL reduction.
But they thought Mevacor and Lopid were the same on HDL improvement — a clear misperception.
The truth: Lopid had a real advantage on HDL. And no one knew it.
Strategic Moves (Powered by CVA):
- Identified the Real Influence Point: General Practitioners
The VP of marketing commissioned focus groups with cardiologists, internists, and general practitioners. CVA segmentation showed that:
- Cardiologists knew the data and rated Lopid higher on HDL.
- Internists were mixed.
- General practitioners (GPs) — who wrote the majority of cholesterol prescriptions — rated the two drugs equal on HDL improvement.
This was the leverage point: Educate GPs, shift prescribing.
- Laser-Focused Education Campaign
- The brand stopped wasting budget on general ads.
- Instead, they hired expert physician-educators to conduct 1:1 detail visits with GPs, backed by the latest peer-reviewed studies and real-world case examples.
- Materials were tailored to highlight HDL-focused patients — a high-risk, underserved segment.
- Framed the Product for Its Ideal Patient
Rather than trying to match Mevacor head-to-head, they shifted positioning:
“Lopid: For patients with dangerously low HDL — when you need to raise the good cholesterol.”
This segment-based strategy was grounded directly in CVA attribute-level worth analysis.
The Result:
- Share stabilized, then rebounded, as GPs began prescribing Lopid for HDL-risk patients.
- The team avoided expensive head-on marketing battles with Merck.
- Sales grew, and Lopid returned to being a major profit driver.
- Meanwhile, the R&D team quietly prepared Lipitor — which would go on to become the most successful statin in history.
And how did they track progress?
They installed a “mini war room” display right next to the brand team’s coffee station — tracking monthly prescription share by doctor type. Every tick upward reminded them: we’re winning because we understand our value.
Why It Worked:
“The data was already out there. What CVA gave us was the lens to see it — and the courage to act on it with precision.”
— [Senior Brand Manager, Lopid]
Rather than react emotionally to a blockbuster competitor, CVA helped the team focus on their unique advantage — and the exact audience that needed to hear it.